 The present phase II study in 20 patients with BRAFV600E mutant, unresectable stage IIIIV melanoma is designed to explore the mechanisms by which tumors acquire resistance to the combination of BRAF and MEK inhibition. Overall response rate and duration to this combination will also be assessed. 